Medipost Names Min Ho-sung Co-CEO Alongside Oh Won-il

By Public Technologies
  • Medipost appointed Min Ho-sung as co-CEO and executive director on Oct. 29, 2026.
  • The shift to an independent co-CEO structure aims to improve management expertise and efficiency.
  • Min previously served as Samsung Biologics vice president from Sept. 4, 2023, to March 31, 2026.
  • He was CEO of GenScript ProBio from April 1, 2019, to June 30, 2023.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medipost Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261029900785), on October 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.